Skip to main content

Advertisement

Table 3 Clinicopathological parameters and the expression of miR − 204-5p in LUSC. Annotation: LUSC, lung squamous cell carcinoma. The rest were the same as Table 1. a, paired sample’s t test performed to compare miR-204-5p expression between NSCLC and the controls; Independent sample’s t test processed to assess relationships between miR-30d-5p expression and the clinicopathological parameters of NSCLC. TNM, tumor, node, metastasis; b, One-way ANOVA preformed to evaluate distributive feature of miR-204-5p in three or more groups of clinicopathological parameters

From: Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses

Clinicopathological parametersnRelevant expression of miR-204-5p (2−ΔCq)
Mean ± SDt/F-valuep-value
TissueLUSC234.6870 ± 1.80638-2.264a0.029
Non-cancer236.0217 ± 2.17547
GenderMale184.8556 ± 1.680410.8440.408
Female54.0800 ± 2.31452
Age (years)< 60154.6933 ± 1.525720.0200.985
> = 6084.6750 ± 2.36628
SmokeNo124.8500 ± 1.724950.4440.662
Yes114.5091 ± 1.95931
Tumor size<=3 cm74.3857 ± 1.96759−0.5200.608
> 3 cm164.8188 ± 1.78222
Vascular invasionNo204.6150 ± 1.86471−0.4850.633
Yes35.1667 ± 1.56950
TNMI-II104.9700 ± 2.215120.6500.523
III-IV134.4692 ± 1.47783
Lymph node metastasisNo114.8364 ± 2.282660.3640.721
Yes124.5500 ± 1.32150
Pathological gradingI0 0.038b0.848
II164.6375 ± 1.80032
III74.8000 ± 1.95959